Gene signature transfer to large HNSCC cohorts allowed to identify a 5-gene prognostic signature and integrin β4 as a promising target to suppress EGF-induced cell invasion and predict tumor budding and response to Cetuximab. The gene discussed is EGF; the disease is head and neck squamous cell carcinoma.